Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.  

Brian M. Culley , Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter.  We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose." 

Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."

The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers.  The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial.  Sixty subjects will be enrolled.  Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.  The C
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner ... mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome ... undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. ...
(Date:6/30/2015)... CO (PRWEB) , ... June 30, 2015 , ... ... today announced that it has hired Gem Swartz to head up its account management ... senior account director. Both Gem and Amanda bring senior account management and delivery expertise ...
(Date:6/30/2015)... 2015  The Dr. Samadi Prostate Cancer Center in ... full suite of new genetic testing methods for men with ... prostate cancer. Dr. Samadi,s Prostate Cancer ... assessing the risk and optimizing the diagnosis of prostate cancer, ... to now offer these revolutionary genetic tests to men with ...
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making ... Featuring 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter ... deep into the NIR range. Previous spectrophotometer calibration standards, such as those made from ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Matrix Marketing Group Expands Client Services Team 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... , WAYNE, N.J., Sept. 24 ... of Surgery and Director of Coronary Surgery and Advanced Coronary ... has completed the world,s first use of the MAQUET Minimized ... endoscopic heart surgery. The new cardiopulmonary bypass technology is the ...
... , SALT LAKE CITY, Sept. ... through the development of molecular diagnostics, announced today that its ... spine specialists in the United States. SCOLISCORE is a saliva-based ... scoliosis, an abnormal lateral curvature of the spine. Spine surgeons ...
... /PRNewswire-Asia-FirstCall/ --, -- Q4 FY 2009 Revenues increased 43.2% to ... $2.2 Million with diluted EPS of $0.08, -- FY 2009 ... Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS of ... to $8.3 Million, -- June 30, 2009 Cash and equivalents ...
Cached Biology Technology:MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 2Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 2Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 4Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 5Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 6Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 7Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 8Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 9Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 10Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 11Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 12
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... and Harvard Medical School have shown how a key ... triggering other changes that allow the AIDS virus to ... Feb. 24 issue of the journal Nature, offer clues ... Researchers led by Howard Hughes Medical Institute Investigator Stephen ...
... human embryonic,stem cells have been contaminated with a ... human subjects,according to research by investigators at the ... and the Salk Institute in La Jolla,California.,In a ... journal Nature,Medicine, the researchers found that human embryonic ...
... available. However, a,similar and equally dangerous addiction, alcoholism, ... be? Researchers from the University of,California in San ... addiction in rodents. We can only hope that ... close future; it would help fix a,problem that ...
Cached Biology News:Elusive HIV shape change revealed; Key clue to how virus infects cells 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4Controversial drug shown to act on brain protein to cut alcohol use 2Controversial drug shown to act on brain protein to cut alcohol use 3
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
...
... Platypus Contact Printing Kit contains choice of ... series of 100 / 200 micron squares ... 200 um x 10 mm lines, 3 ... 40 or 60 nm and pitch of ...
...
Biology Products: